awmsg logo



macitentan (Opsumit®)


Reference No. 711

Publication date:
11/01/2016


Appraisal information

macitentan (Opsumit®) 10 mg film-coated tablet


Company: Actelion Pharmaceuticals UK Ltd
BNF category: Cardiovascular system
NMG meeting date: 04/11/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 4215
Ministerial ratification: 06/01/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Macitentan (Opsumit®) is recommended as an option for use within NHS Wales as monotherapy or in combination for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download